Skip to content

CancerIndexthe global index of cancer

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Pulse Data updates Year in cancer Taxonomy Countries Compare Trial intelligence Trial map Drug pipeline Sources Methodology About Trust & policies Data downloads Developers (API)

Loading cancer entity…

CancerIndex

CancerIndex is a research and information platform. It is not a physician, does not diagnose, and does not recommend treatment. Population statistics do not predict individual outcomes.

Every number links to its source and retrieval date. Derived metrics carry a formula version. AI-generated synthesis is not enabled in this phase; all content is database-grounded.

About Trust & policies Data explorer Data downloads Pulse Data update log Developers (API)Sources Methodology Taxonomy Countries Compare Contact · contact@spboucher.ai Status

© 2026 CancerIndex · built and maintained by Simon-Pierre Boucher · contact contact@spboucher.ai · hosted on MacLustr (www.maclustr.io). Source data remains under the license of each provider — see /sources.

Neck Neoplasm — Research · CancerIndex

Cancers
Neoplasm
Neoplasm by Site
Head and Neck Neoplasm
Neck Neoplasm

Cancer Family

Neck Neoplasm

CI-CAN-00000283Explore in graph →

Non-malignant634 active trials11 approved drugs67 evidence items

NCIt: C3260

Overview
Statistics
Survival
Genomics7
Variants & evidence67
Drugs19
Trials2377
Research
Rankings
Sources & provenance

Research activity

PubMed record counts

Each count is the number of PubMed records returned by the exact query shown, at the time it was run. Counts are research-activity signals, not quality measures.

Data not yet available

No PubMed query has been run for this entity. Counts require a MeSH-anchored query built from the entity's terminology mappings; the query string is stored with each count so it can be reproduced.

What CancerIndex knows

Trials tab
Methodology: publication counts

Literature

Linked publications (195)

Publications linked to this entity or its descendants, newest first, 25 per page. Link method and validation status are shown; 'candidate' links have not been reviewed.

pubmedProvenance

Source: PubMed (NLM)
Dataset: PubMed E-utilities
Retrieved: Sep 8, 2026
Layer: normalized (units and labels harmonized; values unchanged)

PublishedShowing 151–175 of 195 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

BRAF V600E and TERT promoter mutations cooperatively identify the most aggressive papillary thyroid cancer with highest recurrence.
· J Clin Oncol · 2014 · PMID 25024077 · validated civic_curation pubmed
Oncogenic AKAP9-BRAF fusion is a novel mechanism of MAPK pathway activation in thyroid cancer.
· J Clin Invest · 2005 · PMID 15630448 · validated civic_curation pubmed
Association of Human Papillomavirus and p16 Status With Outcomes in the IMCL-9815 Phase III Registration Trial for Patients With Locoregionally Advanced Oropharyngeal Squamous Cell Carcinoma of the Head and Neck Treated With Radiotherapy With or Without Cetuximab.
· J Clin Oncol · 2016 · PMID 26712222 · validated civic_curation pubmed
BRAF(V600E) mutation and outcome of patients with papillary thyroid carcinoma: a 15-year median follow-up study.
· J Clin Endocrinol Metab · 2008 · PMID 18682506 · validated civic_curation pubmed
When is prophylactic thyroidectomy indicated for patients with the RET codon 609 mutation?
· Ann Surg Oncol · 2009 · PMID 19472011 · validated civic_curation pubmed
Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations.Retracted
· N Engl J Med · 2015 · PMID 26287849 · validated civic_curation pubmed
Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study.

Showing 151–175 of 195 publications

← Previous
1
…
6
7
8
Next →

· J Clin Oncol · 2018 · PMID 29320312 · validated civic_curation pubmed

Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic BRAF V600-Mutant Anaplastic Thyroid Cancer.

· J Clin Oncol · 2018 · PMID 29072975 · validated civic_curation pubmed

Correlative analyses of RET and RAS mutations in a phase 3 trial of cabozantinib in patients with progressive, metastatic medullary thyroid cancer.

· Cancer · 2016 · PMID 27525386 · validated civic_curation pubmed

Vemurafenib in patients with BRAF(V600E)-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trial.

· Lancet Oncol · 2016 · PMID 27460442 · validated civic_curation pubmed

BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer.

· J Clin Endocrinol Metab · 2005 · PMID 16174717 · validated civic_curation pubmed

Prognostic significance of somatic RET oncogene mutations in sporadic medullary thyroid cancer: a 10-year follow-up study.

· J Clin Endocrinol Metab · 2008 · PMID 18073307 · validated civic_curation pubmed

Both BRAF V600E mutation and older age (≥ 65 years) are associated with recurrent papillary thyroid cancer.

· Ann Surg Oncol · 2011 · PMID 21594703 · validated civic_curation pubmed

Prognostic value of the BRAF V600E mutation in papillary thyroid carcinoma.

· Oncol Lett · 2014 · PMID 24396464 · validated civic_curation pubmed

The associations between RAS mutations and clinical characteristics in follicular thyroid tumors: new insights from a single center and a large patient cohort.

· Thyroid · 2012 · PMID 22650231 · validated civic_curation pubmed

RAS point mutations and PAX8-PPAR gamma rearrangement in thyroid tumors: evidence for distinct molecular pathways in thyroid follicular carcinoma.

· J Clin Endocrinol Metab · 2003 · PMID 12727991 · validated civic_curation pubmed

Highly prevalent TERT promoter mutations in aggressive thyroid cancers.

· Endocr Relat Cancer · 2013 · PMID 23766237 · validated civic_curation pubmed

Programmed death-ligand 1 overexpression is a prognostic marker for aggressive papillary thyroid cancer and its variants.

· Oncotarget · 2016 · PMID 27086918 · validated civic_curation pubmed

Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer.

· J Clin Oncol · 2010 · PMID 20368568 · validated civic_curation pubmed

Diagnostic and prognostic TERT promoter mutations in thyroid fine-needle aspiration biopsy.

· Endocr Relat Cancer · 2014 · PMID 25121551 · validated civic_curation pubmed

The association of the BRAF(V600E) mutation with prognostic factors and poor clinical outcome in papillary thyroid cancer: a meta-analysis.

· Cancer · 2012 · PMID 21882184 · validated civic_curation pubmed

NTRK fusion oncogenes in pediatric papillary thyroid carcinoma in northeast United States.

· Cancer · 2016 · PMID 26784937 · validated civic_curation pubmed

Re: "A Case Report of Poor Response to Selpercatinib in the Presence of a 632_633 RET Deletion" by Wijewardene et al.

· Thyroid · 2023 · PMID 37376747 · validated civic_curation pubmed

Genotype-phenotype correlation of patients with multiple endocrine neoplasia type 2 in Japan.

· Jpn J Clin Oncol · 1998 · PMID 9839497 · validated civic_curation pubmed

SHP2 promotes laryngeal cancer growth through the Ras/Raf/Mek/Erk pathway and serves as a prognostic indicator for laryngeal cancer.

· Int J Oncol · 2014 · PMID 24297342 · validated civic_curation pubmed